Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASCO 2024 | Development of AdAPT-001, a novel TGF-β-trap-enhanced oncolytic virus

Lucy Kennedy • 2 Jun 2024

ASCO 2024

General AdAPT-001 Antibodies Checkpoint Inhibitors

Lucy Kennedy, MD, Cleveland Clinic, Cleveland, OH, provides an overview of AdAPT-001, an oncolytic adenovirus combined with a TGF-β trap. The novel drug will aim to overcome checkpoint inhibitor resistance by inhibiting the activity of TGF-β and enhancing immune responses. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Phase I/II trial of AdAPT-001, an oncolytic virus, and a checkpoint inhibitor in solid tumors

Phase I/II trial of AdAPT-001, an oncolytic virus, and a checkpoint inhibitor in solid tumors

Lucy Kennedy • 2 Jun 2024

$The future of AdAPT-001 in patients with solid tumors refractory to checkpoint inhibitors$

The future of AdAPT-001 in patients with solid tumors refractory to checkpoint inhibitors

Lucy Kennedy • 2 Jun 2024

Related Videos

AI governance and validation in robotic cancer surgery

AI governance and validation in robotic cancer surgery

Marie Hanaoka • 1 Jul 2026

Does toxicity differ between patients treated with SABR for one versus five lesions?

Does toxicity differ between patients treated with SABR for one versus five lesions?

Robert Olson • 16 May 2026

5-year toxicity following SABR: insights from the SABR-5 trial

5-year toxicity following SABR: insights from the SABR-5 trial

Robert Olson • 16 May 2026

How should results from the SABR-5 trial guide future SABR studies?

How should results from the SABR-5 trial guide future SABR studies?

Robert Olson • 16 May 2026